

Natasha Rekhtman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/383426/publications.pdf>

Version: 2024-02-01

143
papers

23,691
citations

24978

57
h-index

11288

136
g-index

146
all docs

146
docs citations

146
times ranked

26271
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585.	7.7	48
2	Lung neuroendocrine neoplasms: recent progress and persistent challenges. <i>Modern Pathology</i> , 2022, 35, 36-50.	2.9	74
3	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	0.5	429
4	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	5.8	47
5	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 515-528.	1.2	12
6	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. <i>Radiology</i> , 2022, 303, 664-672.	3.6	28
7	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 793-805.	0.5	6
8	Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management. <i>Journal of Thoracic Oncology</i> , 2022, 17, e50-e51.	0.5	0
9	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
10	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, 2144.	5.8	18
11	Clinical outcomes of immune checkpoint inhibitors in <i>HER2</i> -amplified non-small cell lung cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, e21098-e21098.	0.8	1
12	POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1109-1121.	0.5	29
13	AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in <i>EGFR</i> -mutant lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, e21166-e21166.	0.8	0
14	Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3. <i>Human Pathology</i> , 2022, 127, 102-111.	1.1	4
15	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. <i>Clinical Cancer Research</i> , 2022, 28, 4702-4713.	3.2	25
16	Percutaneous computed tomography guided biopsy of sub-solid pulmonary nodules: differentiating solid from ground glass components at the time of biopsy. <i>Clinical Imaging</i> , 2021, 69, 332-338.	0.8	7
17	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1316-1328.	3.2	39
18	<i>MET</i> Exon 14 "altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	3.2	35

#	ARTICLE	IF	CITATIONS
19	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, e205601.	2.2	52
20	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. <i>Lung Cancer</i> , 2021, 153, 158-164.	0.9	4
21	Rapid EGFR Mutation Detection Using the Idylla Platform. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 310-322.	1.2	19
22	Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9049-9049.	0.8	0
23	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	3.2	45
24	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	7.7	66
25	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
26	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1149-1165.	0.5	18
27	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3656.	1.7	8
28	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1188-1199.	0.5	23
29	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. <i>Nature Communications</i> , 2021, 12, 4789.	5.8	21
30	Spread Through Air Spaces (STAS) in Non-Small Cell Lung Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1509-1515.	2.1	14
31	Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor. <i>American Journal of Clinical Pathology</i> , 2021, 155, 832-844.	0.4	20
32	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 5-12.	0.6	26
33	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. <i>Cancer Cell</i> , 2021, 39, 1479-1496.e18.	7.7	155
34	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.	6.9	26
35	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 589-600.	0.5	55
36	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	0.5	172

#	ARTICLE	IF	CITATIONS
37	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	0.5	234
38	Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 860-878.	1.3	31
39	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444.	2.9	118
40	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13.	7.7	210
41	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	3.2	133
42	CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	1.5	14
43	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
44	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. <i>Journal of Thoracic Oncology</i> , 2020, 15, e121-e124.	0.5	5
45	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	12.5	165
46	Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. <i>Histopathology</i> , 2020, 77, 915-925.	1.6	92
47	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.	1.1	46
48	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
49	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. <i>Journal of Thoracic Oncology</i> , 2020, 15, e118-e120.	0.5	6
50	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. <i>Modern Pathology</i> , 2020, 33, 2244-2255.	2.9	23
51	Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile. <i>Cancer Cytopathology</i> , 2020, 128, 414-423.	1.4	8
52	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. <i>Nature Medicine</i> , 2020, 26, 259-269.	15.2	274
53	“Napoleon Hat” Sign: A Distinctive Cytologic Clue to Reactive Pneumocytes. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 443-445.	1.2	2
54	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	3.2	230

#	ARTICLE	IF	CITATIONS
55	An update on touch preparations of small biopsies. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 322-331.	0.2	14
56	Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100077.	0.6	18
57	Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 9018-9018.	0.8	1
58	<i>YES1</i> amplification as a primary driver of lung tumorigenesis and <i>YES1/YAP1</i> amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs). <i>Journal of Clinical Oncology</i> , 2020, 38, e21591-e21591.	0.8	0
59	CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki67 clone 30 is not susceptible to the inhibition: Critical diagnostic implications. <i>Cancer Cytopathology</i> , 2019, 127, 643-649.	1.4	21
60	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at Risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	0.5	232
61	Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids. <i>Cancer Research</i> , 2019, 79, 4339-4347.	0.4	47
62	Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1125-1127.	0.5	21
63	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1583-1593.	0.5	55
64	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1948-1961.	0.5	35
65	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	3.2	69
66	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7475-7484.	3.2	30
67	Immunophenotype and Response to Immunotherapy of <i>RET</i> -Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	73
68	Immunostains: Solid Tumors. , 2019, , 23-48.		0
69	Grading (and Classification) Systems Quick Reference: Solid Tumors. , 2019, , 93-111.		0
70	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. <i>Cancer Cytopathology</i> , 2019, 127, 325-339.	1.4	78
71	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. <i>Modern Pathology</i> , 2019, 32, 1106-1122.	2.9	58
72	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003665.	0.5	23

#	ARTICLE	IF	CITATIONS
73	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	0.5	212
74	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 87-98.	0.5	153
75	Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8556-8556.	0.8	2
76	MET inhibitor resistance in patients with MET exon 14-altered lung cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9006-9006.	0.8	24
77	Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9028-9028.	0.8	22
78	Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3129-3129.	0.8	0
79	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	7.7	149
80	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
81	Commentary on Testing of Non-Adenocarcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 798-798.	1.2	2
82	Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1537-1548.	1.2	9
83	Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. <i>Lung Cancer</i> , 2018, 119, 85-90.	0.9	38
84	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. <i>Modern Pathology</i> , 2018, 31, 111-121.	2.9	50
85	Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 529-535.	1.2	30
86	Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 253-259.	0.9	19
87	Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	60
88	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
89	Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-7.	0.7	11
90	Bronchiolar Adenoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1010-1026.	2.1	91

#	ARTICLE	IF	CITATIONS
91	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	1.6	1
92	Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. <i>Cancer Cytopathology</i> , 2017, 125, 188-196.	1.4	13
93	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017, 31, 286-299.	7.7	370
94	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
95	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	0.9	42
96	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e81-e83.	1.1	1
97	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 223-234.	0.5	134
98	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535.	3.2	252
99	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	1.1	54
100	Cytology Specimens: A Goldmine for Molecular Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1189-1190.	1.2	35
101	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1267-1272.	1.2	95
102	Molecular Assessment of Multiple Pulmonary Carcinomas: An Evolving Area. <i>Journal of Thoracic Oncology</i> , 2016, 11, e54.	0.5	0
103	Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1116-1120.	1.2	22
104	Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1200-1205.	1.2	72
105	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	5.1	365
106	Standardized terminology and nomenclature for respiratory cytology: The American Society of Cytopathology guidelines. <i>Diagnostic Cytopathology</i> , 2016, 44, 399-409.	0.5	57
107	An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4880-4889.	3.2	140
108	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	1.1	116

#	ARTICLE	IF	CITATIONS
109	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
110	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-like Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	3.2	342
111	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1170-1180.	2.1	61
112	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. <i>Cancer Discovery</i> , 2015, 5, 842-849.	7.7	514
113	Nonspecific Reactivity of Polyclonal Napsin A Antibody in Mucinous Adenocarcinomas of Various Sites: A Word of Caution. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 434-436.	1.2	10
114	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Oncology Practice</i> , 2015, 11, 135-136.	2.5	20
115	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. <i>Cancer Discovery</i> , 2015, 5, 610-621.	7.7	129
116	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
117	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of accuracy and interobserver agreement. <i>Histopathology</i> , 2015, 66, 922-938.	1.6	127
118	Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7518-7518.	0.8	1
119	Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. <i>Human Pathology</i> , 2014, 45, 213-220.	1.1	73
120	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3673-3679.	0.8	251
121	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. <i>Nature</i> , 2014, 516, 423-427.	13.7	538
122	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. <i>Journal of Thoracic Oncology</i> , 2014, 9, 892-896.	0.5	106
123	Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles. <i>Journal of Thoracic Oncology</i> , 2014, 9, e1-e3.	0.5	6
124	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1307-1319.	2.9	102
125	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 2240-2247.	3.2	2,097
126	<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 220-229.	1.9	367

#	ARTICLE	IF	CITATIONS
127	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. <i>Modern Pathology</i> , 2013, 26, 511-522.	2.9	95
128	Response to Erlotinib in Patients with <i>EGFR</i> Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2535-2540.	1.9	46
129	β -Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. <i>Journal of Thoracic Oncology</i> , 2012, 7, 281-290.	0.5	126
130	ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 768-769.	0.5	47
131	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. <i>Lancet Oncology</i> , The, 2012, 13, e418-e426.	5.1	178
132	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of <i>EGFR</i> and <i>KRAS</i> and Presence of <i>PIK3CA</i> and <i>AKT1</i> Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 1167-1176.	3.2	342
133	p40 (β -Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 405-415.	2.9	343
134	Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. <i>Cancer Cytopathology</i> , 2012, 120, 35-43.	1.4	32
135	Multiplex testing for driver mutations in squamous cell carcinomas of the lung.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7505-7505.	0.8	21
136	Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma. <i>Pathology Research International</i> , 2011, 2011, 1-7.	1.4	33
137	Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1849-1856.	0.5	121
138	Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. <i>Modern Pathology</i> , 2011, 24, 1348-1359.	2.9	299
139	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 022-031.	0.8	140
140	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of <i>EGFR</i> and <i>KRAS</i> Molecular Testing. <i>Journal of Thoracic Oncology</i> , 2011, 6, 451-458.	0.5	230
141	Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. <i>Journal of Thoracic Oncology</i> , 2010, 5, 411-414.	0.5	172
142	Progenitor stem cell marker expression by pulmonary carcinomas. <i>Modern Pathology</i> , 2010, 23, 889-895.	2.9	56
143	Neuroendocrine Tumors of the Lung: An Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1628-1638.	1.2	355